Quick Answer
PharmaCyte Biotech, Inc. reported Total Assets of $55.17 million for the year ending 2025.
- PharmaCyte Biotech, Inc. showed a decrease of -7.9% in Total Assets from 2024 to 2025.
- This data is from PharmaCyte Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on August 11, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $1.73 million | Q1 2012: $1.86 million | Q3 2012: $2.23 million | Q4 2012: $2.32 million | Q1 2013: $2.45 million | Q3 2013: $3.39 million | Q4 2013: $4.59 million | Q1 2014: $5.66 million | Q3 2014: $8.20 million | Q4 2014: $6.66 million | Q1 2015: $6.63 million | Q3 2015: $8.14 million | Q4 2015: $7.64 million | Q1 2016: $8.00 million | Q4 2016: $6.73 million | Q3 2017: $9.52 million | Q4 2017: $7.92 million | Q1 2018: $6.73 million | Q3 2018: $7.08 million | Q4 2018: $6.07 million | Q1 2019: $5.84 million | Q3 2019: $5.61 million | Q4 2019: $5.34 million | Q1 2020: $5.34 million | Q3 2020: $7.43 million | Q4 2020: $8.94 million | Q1 2021: $8.26 million | Q3 2021: $6.64 million | Q4 2021: $92.31 million | Q1 2022: $91.94 million | Q3 2022: $87.39 million | Q4 2022: $82.35 million | Q1 2023: $77.95 million | Q3 2023: $79.88 million | Q4 2023: $78.88 million | Q1 2024: $71.36 million | Q3 2024: $70.19 million | Q4 2024: $55.10 million | Q1 2025: $43.83 million | Q2 2025: $55.17 million | Q3 2025: $45.11 million | Q4 2025: $55.98 million | Q1 2026: $55.87 million.
- Over the full 15 years of available data (2011 to 2025), PharmaCyte Biotech, Inc.'s Total Assets has grown by 4,348.4%.
- Historical annual values: Fiscal year 2025: $55.17 million | Fiscal year 2024: $59.90 million | Fiscal year 2023: $73.28 million | Fiscal year 2022: $90.62 million | Fiscal year 2021: $7.40 million | Fiscal year 2020: $6.17 million | Fiscal year 2019: $5.78 million | Fiscal year 2018: $6.41 million | Fiscal year 2017: $8.67 million | Fiscal year 2016: $7.16 million | Fiscal year 2015: $9.30 million | Fiscal year 2014: $9.32 million | Fiscal year 2013: $2.88 million | Fiscal year 2012: $2.09 million | Fiscal year 2011: $1.24 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: